APLT Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Applied Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.01 |
| 52 Week High | US$10.62 |
| 52 Week Low | US$1.79 |
| Beta | 2.02 |
| 11 Month Change | -1.42% |
| 3 Month Change | 54.02% |
| 1 Year Change | 355.05% |
| 33 Year Change | -26.33% |
| 5 Year Change | -44.28% |
| Change since IPO | -4.15% |
Recent News & Updates
Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review
Sep 18Applied Therapeutics: Pushing Towards FDA Approval
Sep 04We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely
Aug 01
Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases
May 28Recent updates
Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review
Sep 18Applied Therapeutics: Pushing Towards FDA Approval
Sep 04We're Hopeful That Applied Therapeutics (NASDAQ:APLT) Will Use Its Cash Wisely
Aug 01Applied Therapeutics: Navigating Challenges In ARI Development For Rare Diseases
May 28Applied Therapeutics: Speedy Regulatory Review Of Govorestat Might Be Possible
Feb 16Is Applied Therapeutics (NASDAQ:APLT) In A Good Position To Deliver On Growth Plans?
Feb 16Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?
Nov 13We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate
Aug 11We're A Little Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Rate
May 19Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock
Jan 19Is Applied Therapeutics (NASDAQ:APLT) Using Debt In A Risky Way?
Nov 11Here's Why We're Watching Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation
Aug 13Applied Therapeutics trades higher on FDA Fast Track designation for rare metabolic disorder
Jun 17Will Applied Therapeutics (NASDAQ:APLT) Spend Its Cash Wisely?
May 15Independent Director Stacy Kanter Just Bought 100% More Shares In Applied Therapeutics, Inc. (NASDAQ:APLT)
Feb 26How Much Of Applied Therapeutics, Inc. (NASDAQ:APLT) Do Insiders Own?
Feb 18Applied Therapeutics to resume galactosemia study for AT-007
Feb 02Applied Therapeutics, Inc. (NASDAQ:APLT) Insiders Have Been Selling
Nov 24
Applied Therapeutics EPS misses by $0.21
Nov 12Shareholder Returns
| APLT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.5% | -5.8% | -0.5% |
| 1Y | 355.1% | 20.8% | 32.3% |
Return vs Industry: APLT exceeded the US Biotechs industry which returned 22.2% over the past year.
Return vs Market: APLT exceeded the US Market which returned 33.1% over the past year.
Price Volatility
| APLT volatility | |
|---|---|
| APLT Average Weekly Movement | 20.8% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: APLT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: APLT's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 37 | Shoshana Shendelman | www.appliedtherapeutics.com |
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company’s lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy.
Applied Therapeutics, Inc. Fundamentals Summary
| APLT fundamental statistics | |
|---|---|
| Market cap | US$1.04b |
| Earnings (TTM) | -US$187.31m |
| Revenue (TTM) | n/a |
-4,945x
P/S Ratio-5.6x
P/E RatioIs APLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APLT income statement (TTM) | |
|---|---|
| Revenue | -US$212.00k |
| Cost of Revenue | US$52.35m |
| Gross Profit | -US$52.56m |
| Other Expenses | US$134.75m |
| Earnings | -US$187.31m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.61 |
| Gross Margin | 24,794.34% |
| Net Profit Margin | 88,353.77% |
| Debt/Equity Ratio | 0% |
How did APLT perform over the long term?
See historical performance and comparison